Researchers are also
studying ovarian tissue transplantation for patients with cancer.
Not exact matches
In this
study, researchers analyzed
ovarian tissue from populations of reproductively «young» (equivalent to women in their early twenties) and «old» mice (equivalent to women ages 38 - 45).
«
Ovarian cancer treatments have not changed much in many decades, and this may be, in part, because we have been
studying the wrong
tissue of origin for these cancers,» says
study leader Victor Velculescu, M.D., Ph.D., a professor of oncology at the Johns Hopkins Kimmel Cancer Center.
For the new
study, described in the October 23rd issue of Nature Communications, scientists at the Johns Hopkins Kimmel Cancer Center and Dana Farber Cancer Institute in Boston collected
tissue samples containing normal cells,
ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC lesions.
The
study team assessed three sets of outcomes: a maturational index (MI) based on epithelial cells from the children's urogenital
tissue; ultrasound measurements of uterine,
ovarian and testicular volume, as well as breast - buds; and hormone concentrations seen in blood tests.
Cancer patients who have
ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new
study finds.
«This fatty
tissue, which is extraordinarily rich in energy - dense lipids, acts as a launching pad and energy source for the likely lethal spread of
ovarian cancer,» said
study author Ernst Lengyel, MD, PhD, professor of obstetrics and gynecology at the University of Chicago.
Clinical and laboratory
studies have shown that NY - ESO - 1 is present in many different cancers — including melanoma, lung, breast, and
ovarian cancers — and not in most healthy
tissue.
According to the
study authors,
tissue and fluid collected during a Pap test can detect endometrial and
ovarian cancer in women when subjected to genetic testing.
The good news is that if markers for these tubal cells can be found, then blood tests, advanced Pap smears, or direct tests on tubal
tissue might spot
ovarian cancer earlier, the
study authors said.